Back to results
US 10,119,976 B2Granted
Method of assessing risk of PML
AssigneeBiogen MA Inc.
InventorsGary Lewis Bloomgren, Carmen Bozic, Sophia Lee, Amy Pace, Tatiana Plavina, Meena Subramanyam
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
Claims26
A method of evaluating a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML), the method comprising:
- determining a JC virus (JCV) antibody titer in a biological sample from the patient, wherein the patient has a negative prior immunosuppressant exposure classification;
- wherein
- if the titer is determined to be above a pre-determined level, the patient is determined to be at a higher risk of developing PML, and wherein
- if the titer is determined to be at or below an index level of 0.9, the patient is determined to be at a lower risk of developing PML.
1 more element
A method of evaluating a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML), the method comprising:
- determining a JC virus (JCV) antibody titer in a biological sample from the patient, wherein the patient has a negative prior immunosuppressant exposure classification;
- wherein
- if the titer is determined to be at or below an index level of 0.9, the patient is determined to be at a lower risk of developing PML.
A method of treating an MS patient, comprising:
- administering an anti-VLA4 antibody responsive to a determination of a JC virus (JCV) antibody titer at or below an index level of 0.9 in a patient having a negative prior immunosuppressant exposure classification, thereby treating the patient.
Dependencies are inferred from the claim text.